Assessment of a new transtelephonic portable spirometer

Shimon Abboud, Israel Bruderman

Abstract

Background – A new portable spirometer, the Spirophone, has been developed that records a subject’s blow and can then transmit all the data by telephone to a receiving centre for analysis and comment. Tests of this device were undertaken to determine its accuracy and reliability.

Methods – The performance of the Spirophone was tested using computer generated wave forms, by delivering blows from calibrated syringes at different flows, and by comparing subjects’ blows with those recorded with a commercial spirometer.

Results – Using computer generated wave forms all lung function indices were accurate to within 1% and blows delivered from calibrating syringes were accurate to within 5%. When subjects performed repeated forced vital capacity (FVC) manoeuvres there were no significant differences between lung function indices recorded with the Spirophone and with a commercial spirometer. With the Spirophone and commercial spirometer in series the FVC and forced expiratory volume in one second (FEV₁) were within 5% of each other in nine out of 10 healthy subjects.

Conclusion – The Spirophone recorded maximal forced expiratory manoeuvres with acceptable accuracy, reliability, and reproducibility, and this system offers the ability to monitor a patient’s lung function at a centre remote from the patient. (Thorax 1996;51:407-410)

Keywords: spirometry, FVC test, lung function parameters.

Home monitoring of lung function is becoming increasingly important in the management of asthma, chronic obstructive lung disease,1,2 and after lung transplantation. The most widely used devices in patient self-monitoring of daily medication and in clinical drug efficacy studies have been peak flow meters, and portable spirometers have also been used to measure forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), and peak expiratory flow (PEF). A transtelephonic portable personal spirometer (Spirophone AG-SP) with a remote receiving centre (CG-8010) has been developed (Card Guard, Rishon Le Zion, Israel) which can measure lung function indices at a patient’s home and transmit the data to a remote receiving centre for analysis of both spiromgrams and flow-volume curves. We have evaluated the accuracy, reliability, and reproducibility of this system in the laboratory and in an operational setting.

Methods

The Spirophone comprises an unheated Fleisch pneumotachograph with differential pressure transducer, microprocessor, memory, and speaker which operates with a 9 volt battery and samples the flow signal at 400 Hz using a 12 bit A/D converter. The flow meter is 150 mm long and accepts standard 28 mm internal diameter mouthpieces. Ambient temperature is recorded to within 1°C during the blow as recommended by the American Thoracic Society,3 and its operational range is up to eight litres in volume, 14 l/s flow, and 30 second duration for recording vital capacity (VC) and up to 25 seconds for FVC. The following spirometric indices are calculated by the microprocessor of the Spirophone: VC, FVC, FEV₁, and FEV₉, PEF, and the maximal expiratory flow when 75%, 50% and 25% of FVC remain to be expired (MEF₇₅, MEF₅₀, and MEF₃₅). The FEV₁ and FEV₉ are calculated using back extrapolation4 and are also expressed as a percentage of VC and FVC (FEV₁/VC, FEV₉/FVC, etc). The Spirophone records one blow at a time and then modulates the data into tones for transmission by telephone to a receiving centre using acoustic coupling. The transmission of data takes 30 seconds which includes the application of a data verification algorithm.

The receiving centre requires a 486 personal computer with 4 Mb RAM, a receiving de-modulator unit, and a printer. On receiving a call from a patient, an operator at the receiving centre instructs the patient to transmit the data by placing the phone handset on to the Spirophone’s speaker. The receiving unit de-modulates the data, performs a BTPS correction (see Appendix), and presents it on screen with the spirogram and flow-volume curve. If the blow is deemed acceptable according to ATS recommendations5 it is then stored in a database and the patient can then be instructed with respect to further blows or their clinical management. The system is only suitable for patients who have been assessed as able to perform the expiratory manoeuvres satisfactorily when unsupervised.

The Spirophone was compared with a commercial Fleisch pneumotachograph electronic spirometer (Fukuda Spiroanalyzer Model ST-250) with an identical operational range but whose heating element we disconnected during measurements with calibrated syringes.
Table 1  Results from testing with analogue signals simulating forced vital capacity manoeuvres

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Patient 1</th>
<th>Patient 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spirophone</td>
<td>Spirometer*</td>
<td>Spirophone</td>
<td>Spirometer*</td>
</tr>
<tr>
<td>SPIV (l)</td>
<td>5.33 (0.09)</td>
<td>5.13 (0.13)</td>
<td>5.53 (0.26)</td>
</tr>
<tr>
<td>PEV (l)</td>
<td>4.29 (0.13)</td>
<td>4.37 (0.06)</td>
<td>3.72 (0.11)</td>
</tr>
<tr>
<td>PEF (l/s)</td>
<td>5.52 (0.02)</td>
<td>5.02 (0.22)</td>
<td>5.70 (0.07)</td>
</tr>
<tr>
<td>MEF_50 (l/s)</td>
<td>10-02 (63)</td>
<td>9.65 (34)</td>
<td>8.95 (68)</td>
</tr>
<tr>
<td>MEF_50 (l/s)</td>
<td>8.98 (0.31)</td>
<td>9.18 (0.07)</td>
<td>5.76 (0.77)</td>
</tr>
<tr>
<td>MEF_50 (l/s)</td>
<td>4.68 (0.24)</td>
<td>4.83 (0.28)</td>
<td>3.44 (0.23)</td>
</tr>
<tr>
<td>MEF_50 (l/s)</td>
<td>2-10 (0.20)</td>
<td>2.38 (0.11)</td>
<td>1.23 (0.10)</td>
</tr>
</tbody>
</table>

* Office spirometer.

The electronic circuitry and microprocessor software of the Spirophone were tested with computer simulated "Gaussian" flow-time signals (symmetric signal around the mean) applied directly to the A/D converter. The linearity of the Spirophone was tested by discharging through the Spirophone a computer driven volume-time ramp profile - that is, constant flow at different flows using a three litre servo-controlled piston pump. One litre and three litre syringes were then discharged through the Spirophone and the commercial spirometer after each was calibrated for ambient temperature with no BTPS correction being applied. The syringes were fitted directly to the spirometers to minimise turbulence and resonance.

Tests with human subjects were conducted with the ambient temperature between 21°C and 23°C and barometric pressure at 750-755 mm Hg. One normal subject and two patients performed 10 repeated FVC manoeuvres separately through each spirometer. The Spirophone and commercial spirometer were then connected in series and 10 normal subjects performed FVC manoeuvres. Fifteen patients (nine women) aged 13-64 years with evidence of airflow limitation performed relaxed and forced VC manoeuvres separately with the Spirophone and commercial spirometer. Three acceptable flows were recorded and the best results were used for analysis. The Spirophone data were transmitted via a telephone in the same room.

For definition of terms see footnote to table 1.

Results

When tested with constant flows up to 14 l/s from a computer driven syringe the linearity of the Spirophone was found to meet the ATS recommendation of ±0.2 l/s or ±5% of the reading, whichever is the greater, with the maximum absolute and percentage error being -0.098 l/s or 8.2% at a flow of 1-24 l/s. Table 1 shows the results when the circuitry of the Spirophone was tested with simulated signals and the greatest error was less than 1%. Figure 1 shows the volumes recorded with the Spirophone when tested with simulating syringes discharged with varying flows. The maximum error was within ±5% of the true value.
Assessment of a new transtelephonic portable spirometer

Table 2 shows the results for 10 repeated FVC manoeuvres for a healthy subject and two patients with different spirometric abnormalities. The reproducibility of the Spirophone was comparable with that for the commercial spirometer and there were no significant differences between the spirometers for any of the lung function indices in any subject.

Figure 2 shows the comparison between the results from 10 subjects recorded with the Spirophone and commercial spirometer connected in series. The FVC and FEV₁ were within ±5% in nine of the 10 subjects, with all the results being within ±7%.

The results for the 15 patients with the Spirophone and the commercial spirometer were analysed according to the method of Altman and Bland \(^1\) and fig 3 shows the plots for FVC, FEV₁, and PEF. The results for all indices are presented in table 3 and show significantly lower readings with the Spirophone for relaxed VC and MEF₂₅ with the differences not being related to the magnitude of the mean for the two spirometers. For all the other indices there was no significant difference and no trend in relation to mean value.

When the Spirophones were tested for three months at home and in the 30 day laboratory based study all performed reliably without recording or transmission failure. A battery change was needed after 90–100 operations. The one litre volume calibrations were all accurate to within 5% throughout.

Discussion

The Spirophone system was reliable and accurate in both the recording and transmission of forced expiratory manoeuvres from a patient’s home to a remote centre for analysis and comment. Such a system may have considerable merit in the management of certain patients. In the last 10–15 years asthma prevalence and mortality has been increasing in the USA \(^1\) and other countries. Many asthmatic subjects perform home monitoring of PEF using simple hand held meters, and this may lead to improved management of their asthma. \(^1\) However, in fatal asthma there is often pathological evidence of severe effects in small airways. \(^1\)

Thus a portable spirometer such as the Spirophone, that is capable of monitoring both large and small airway function and can also verify patient compliance, may be advantageous. This would be especially true for patients living in remote areas or for those who have difficulty in reaching medical help due to disability or other circumstances. The cost of the Spirophone is about £700, the receiving unit is about £4750, and there is the additional cost of the computer at the receiving centre and the operator’s time. However, it is possible that this transtelephonic system of patient administered spirometry may increase the cost effectiveness of patient management by timely intervention with changes in therapy and consequent avoidance of hospital admission. \(^2\)

Our results in the 15 subjects with airways limitation showed less good agreement for indices with a greater reliance on patient effort such as FVC, PEF, and MEF₂₅, with better agreement for FEV₁, MEF₁₀, and MEF₂₅ which are less effort dependent. Similar agreement was found for FVC and FEV₁ by Gunawardena et al \(^4\) in a study in humans. Because humans have their own inherent variability with repeated blows, \(^5\) the wider levels of agreement observed with certain indices may be expected. Our tests with the two spirometers in series may have influenced the readings as a result of cooling and effects on upstream geometry, \(^6\) but it seems unlikely that this could fortuitously lead to such good agreement between the spirometers.

It has previously been shown \(^7\) that accuracy validation of a spirometer with a calibrated syringe alone is not sufficient to demonstrate
Table 3  Mean (SD) results for 15 subjects with airways limitation recorded with the Spirophone and commercial spirometers

<table>
<thead>
<tr>
<th>Spirophone</th>
<th>Commercial</th>
<th>p value</th>
<th>Mean (SD) differences</th>
<th>Limits of agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>VC</td>
<td>3.21 (2.12)</td>
<td></td>
<td>3.44 (2.32)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>FVC</td>
<td>3.43 (2.10)</td>
<td></td>
<td>3.54 (2.13)</td>
<td>NS</td>
</tr>
<tr>
<td>FEV1</td>
<td>2.68 (2.10)</td>
<td></td>
<td>2.68 (2.20)</td>
<td>NS</td>
</tr>
<tr>
<td>PEFR</td>
<td>3.14 (2.15)</td>
<td></td>
<td>3.19 (2.38)</td>
<td>NS</td>
</tr>
<tr>
<td>MEF25</td>
<td>5.16 (2.67)</td>
<td></td>
<td>5.22 (2.64)</td>
<td>NS</td>
</tr>
<tr>
<td>MEF50</td>
<td>3.02 (1.69)</td>
<td></td>
<td>3.00 (1.71)</td>
<td>NS</td>
</tr>
<tr>
<td>MEF75</td>
<td>1.35 (0.83)</td>
<td></td>
<td>1.26 (0.78)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Mean difference = mean of the commercial spirometer reading minus that from the Spirophone together with the limits of agreements for the differences; VC = vital capacity; NS = not significant.

For definition of other terms see footnote to table 1.

how well a spirometer would perform with dynamic patient wave forms, and a sophisti- cated test using a computer-controlled mechanical pump with the 24 wave forms re- commended by the ATS is necessary. In the present study a sophisticated computer-controlled mechanical pump was not available, and since dynamic wave form testing is essential, human data in a variety of test procedures were used.

The Spirophone uses an unheated pneumo- tachograph which may lead to thermal and condensation errors. These effects can be minimised, however, by placing the pneumo- tachograph on a fan blowing ambient air between blows, and any such error would have affected both the spirometers used in our study and so could not have introduced a bias.

The Spirophone system has been shown to be reliable and accurate for forced expi- ratory manoeuvres and can be used as a diagnostic tool in clinical practice, in epidemiological studies, and in clinical drug efficacy studies. It may also overcome some of the limitations of the present home monitoring devices by providing important additional indices from the forced expi- ratory manoeuvre, by displaying spiromograms and flow-volume curves to a technician or phys- ician for analysis, and by allowing quality control over the blows recorded. However, since the blows are performed without visual supervision, the system is suitable only for patients who are able to perform the forced expiratory manoeuvre by themselves and can respond to advice given over the telephone.

Appendix

The BTPS correction was carried out using the formula below which is sufficiently accurate for clinical application:

\[ V_{BTPS} = V_{ATPS} \times \frac{273 + Tpt}{273 + Tpt} \times \frac{Pb - Pb_{opt}}{Pb - Pb_{opt}} \]

where \( V_{ATPS} \) = volume at atmospheric temperature and pressure, \( Tpt \) = patient's temperature (37°C), \( Tpt \) = temperature of the pneumotachometer, \( Pb \) = barometric pressure, \( Pb_{opt} \) = partial pressure of water vapour at head temperature of pneumotachograph, and \( Pb_{opt} \) = partial pressure of water vapour at temperature of patient. \( Pb_{o2}(T) \) was given by:

\[ Pb_{o2}(T) = 13.2 - 0.605 \times T + 0.0411 \times T^2 \]

Assessment of a new transtelephonic portable spirometer.

S Abboud and I Bruderman

Thorax 1996 51: 407-410
doi: 10.1136/thx.51.4.407

Updated information and services can be found at:
http://thorax.bmj.com/content/51/4/407

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/